The JNK-inhibitor-IX, a JNK2-specific ATP-competitive inhibitor, has shown superior effectiveness in halting the progress of PANC-1, the most common cell line in pancreatic cancers that is resistant to JNK inhibition [66,67]. This evidence concerns the gene MAPK8 and familial pancreatic carcinoma.